Filing Details

Accession Number:
0001209191-15-023776
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-03-06 20:03:57
Reporting Period:
2015-03-05
Filing Date:
2015-03-06
Accepted Time:
2015-03-06 20:03:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1516479 Insys Therapeutics Inc. INSY Pharmaceutical Preparations (2834) 510327886
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
938296 H Theodore Stanley C/O Insys Therapeutics, Inc.
444 South Ellis Street
Chandler AZ 85224
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-03-05 6,700 $7.26 7,700 No 4 M Direct
Common Stock Disposition 2015-03-05 6,700 $60.11 1,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2015-03-05 6,700 $0.00 6,700 $7.26
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
23,300 2023-05-13 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,000 Indirect by non-profit corporation
Common Stock 5,100 Indirect by limited partnership
Footnotes
  1. The exercise price reflects a 3-for-2 stock split effected by the Issuer on March 28, 2014.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The Reporting Person disclaims beneficial ownership of the Securities except to the extent of his pecuriniary interest therein.
  4. The option vests in 48 equal monthly installments and will be fully vested and exercisable on May 14, 2017.